Coinciding with the second anniversary of the breakthrough patient-driven research movement, this first of many data releases aims to accelerate progress in metastatic breast cancer research.
The ӳý Cancer Dependency Map team adds CRISPR-based data from 342 cancer cell lines to their growing catalog of genetic dependencies in cancer, and a new method for ensuring that data's accuracy.
Two new computational tools, MSMuTect and MSMutSig, could help reveal how often mutations in common DNA features called microsatellites appear in, and contribute to, cancer.
A mutation pattern or “signature” linked to defects in two genes points to other ways an important DNA repair mechanism can be shut off in breast cancer.
A best-in-class drug screening collection with more than 3,000 clinical drugs. The Repurposing Hub information resource contains extensive curated annotations for each drug, including details about commercial sources of all compounds.
Cancer cells thrive despite harboring mutations that should kill them. By mapping the dependencies cancer cells rely on for survival, researchers hope to reveal new treatment opportunities.
The successful early-stage clinical trial of a personalized cancer vaccine for melanoma represents the culmination of almost a decade’s collaborative work to overcome challenges large and small.